Blackstone Group LP (BX) shares surged 5.09% in pre-market trading on Tuesday, following reports that Bain Capital is nearing a $2.6 billion deal to acquire Healthedge, a company backed by Blackstone.

The Financial Times reported that Bain Capital is close to finalizing the acquisition of Healthedge, a healthcare technology company that has been part of Blackstone's portfolio. This potential deal highlights Blackstone's ability to create value through its investments and could result in a significant return for the private equity giant.

While the news of the potential Healthedge sale appears to be driving the stock's positive momentum, it's worth noting that several analysts have recently adjusted their target prices for Blackstone. Jefferies cut its target price to $154 from $201, Wells Fargo reduced its target to $139 from $160, and Citigroup lowered its target to $137 from $190. Despite these target price reductions, investors seem to be focusing on the potential windfall from the Healthedge deal, pushing the stock higher in early trading.